Akari Therapeutics Plc Anno IPO
Cos'è Anno IPO di Akari Therapeutics Plc?
Anno IPO di Akari Therapeutics Plc è 2013
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su NASDAQ rispetto a Akari Therapeutics Plc
Cosa fa Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Aziende con anno ipo simili a Akari Therapeutics Plc
- AMG Capital Trust II ha Anno IPO di 2012
- Live Nation Entertainment ha Anno IPO di 2012
- MGM Resorts International ha Anno IPO di 2012
- EnerSpar ha Anno IPO di 2012
- The Western Union ha Anno IPO di 2012
- Wameja ha Anno IPO di 2012
- Akari Therapeutics Plc ha Anno IPO di 2013
- Opus Bank ha Anno IPO di 2014
- Recro Pharma Inc ha Anno IPO di 2014
- Radius Recycling ha Anno IPO di 2014
- Progenity ha Anno IPO di 2014
- Axalta Coating Systems Ltd ha Anno IPO di 2014
- Anevia SA ha Anno IPO di 2014